Engineered immune cells primed with decitabine show promise for tough lymphoma
NCT ID NCT04697940
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on cancer cells, and are primed with a drug called decitabine before being given back. The study aims to find the safest dose and see how well it works in up to 33 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Decitabine-primed tandem CD19/CD20 CAR T cells
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat B-cell Non-Hodgkin's lymphoma that has come back or not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants (33). The treatment may cause serious side effects like cytokine release syndrome, and it is not yet proven to work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECITABINE-PRIMED TANDEM CD19/CD20 CAR T CELLS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug boost standard chemo for an aggressive lymphoma?